Sirolimus, also known as rapamycin is an immunosuppressant indicated for prevention of organ rejection in patient receiving a kidney transplant and for treatment of lymphangioleiomyomatosis. Rapamycin is a macrolide compound obtained from Streptomyces hygroscopicus that selectively blocks cytokine production, antibody production, and inhibits T-lymphocyte activation and proliferation. It binds to the immunophilin, FK binding protein producing an immunosuppressive complex. The complex inhibits the activation of the mammalian target of rapamycin which suppresses cytokine-driven T-cell proliferation. Overall it suppresses the body’s immune system.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value and the acceptable surface limit (ASL).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Sirolimus, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.